MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, LRMR had $92,501K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$92,501K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of equity...
    • Maturities of marketable securit...
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses
    • Lease expense
    • Amortization of premium on marke...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Operating expenses
31,117 172,497 --
Other income, net
1,504 6,824 --
Net loss
-29,613 -110,210 --55,463
Stock-based compensation expense
1,979 3,342 -3,662
Lease expense
-85 -148 --133
Depreciation expense
64 175 -175
Amortization of premium on marketable securities
-80 -482 --1,216
Prepaid expenses and other current assets
-578 -1,862 --4,818
Accounts payable
2,925 1,070 -1,722
Accrued expenses
-20,401 37,073 -479
Other assets
-19 -38 --35
Net cash used in operating activities
-44,614 -67,280 --45,921
Purchases of property and equipment
-23 -68
Purchases of marketable securities
-3,458 -80,142
Maturities of marketable securities
29,000 70,500 -113,500
Net cash provided by (used in) investing activities
29,000 67,019 -33,290
Proceeds from issuance of equity securities
108,101 ---
Proceeds from issuance of common stock, net of issuance costs
-65,086 --
Proceeds from exercise of stock options
14 ---
Net cash provided by financing activities
108,115 65,086 -0
Net increase in cash, cash equivalents and restricted cash
92,501 -4,728 69,553 -12,631
Cash, cash equivalents and restricted cash at beginning of period
86,018 90,746 33,824 -
Cash, cash equivalents and restricted cash at end of period
178,519 86,018 90,746 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofequity securities$108,101K Proceeds from exercise ofstock options$14K Maturities of marketablesecurities$29,000K Net cash provided byfinancing activities$108,115K Net cash provided by(used in) investing...$29,000K Net increase incash, cash...$92,501K Canceled cashflow$44,614K Accounts payable$2,925K Stock-based compensationexpense$1,979K Prepaid expenses andother current assets-$578K Depreciation expense$64K Other assets-$19K Net cash used inoperating activities-$44,614K Canceled cashflow$5,565K Other income, net$1,504K Net loss-$29,613K Accrued expenses-$20,401K Canceled cashflow$1,504K Lease expense-$85K Amortization of premium onmarketable securities-$80K Operating expenses$31,117K

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics, Inc. (LRMR)